KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non Operating Income (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Non Operating Income for 15 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 59.35% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.3 million, a 18.21% decrease, with the full-year FY2025 number at $13.3 million, down 18.21% from a year prior.
  • Non Operating Income was $2.0 million for Q4 2025 at Supernus Pharmaceuticals, down from $2.3 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $12.8 million in Q1 2022 to a low of -$4.7 million in Q4 2022.
  • A 5-year average of $2.7 million and a median of $3.6 million in 2024 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: crashed 237.04% in 2021, then surged 2190.91% in 2023.
  • Supernus Pharmaceuticals' Non Operating Income stood at -$4.0 million in 2021, then decreased by 15.39% to -$4.7 million in 2022, then surged by 194.24% to $4.4 million in 2023, then increased by 13.09% to $5.0 million in 2024, then plummeted by 59.35% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Non Operating Income are $2.0 million (Q4 2025), $2.3 million (Q3 2025), and $4.5 million (Q2 2025).